ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) completed the sale of its subsidiary, Shanghai Zhangtou Yaoxin Technology Development, to Shanghai Zhangjiang Group, according to a Friday Hong Kong bourse filing.
The biopharmaceutical firm has already received the first two payment installments of 66.2 million yuan and is set to receive the last one within 10 business days from the date on which the adjusted amount is determined.
The disposal was first announced on Dec. 30, 2024, with ImmuneOnco agreeing to sell the subsidiary for up to 98.2 million yuan.
Shanghai Zhangtou Yaoxin Technology Development was formed to hold an industrial property-holding company in Shanghai.
Shares of the company were down nearly 15% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。